Health
FDA approves new indication for drug to treat pediatric NDO patients – News-Medical.Net
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for…
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients.
Today’s action is a positive step for the treatment of NDO in young patients. Mirabegron,…
-
Noosa News14 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News15 hours agoMotorcyclist dies in crash with truck
-
Noosa News16 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General21 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging